Join us in Barcelona at this year’s ESMO Congress 2024 for a Proffered Paper oral presentation featuring initial data from our first-in-human Phase 1 clinical trial of HST-1011, our novel, selective CBL-B inhibitor. We hope to see you there! https://lnkd.in/gD86Tjhc
About us
Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties.
- Website
-
http://www.hotspotthera.com/
External link for HotSpot Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
Get directions
50 Milk St
Boston, Massachusetts 02109, US
Employees at HotSpot Therapeutics, Inc.
Updates
-
At today’s AACR Advances in Malignant Lymphoma Conference, we’re presenting preclinical data on HST-1021, our MALT1 scaffolding inhibitor. Swing by the poster today at 5:30 PM ET if you’re in Philadelphia! https://lnkd.in/gsTvCE9D
-
-
Check out the latest blog from HotSpot CEO Jonathan Montagu that highlights promising science emerging from the immuno-oncology field in recent months: https://lnkd.in/gV4H6W7i
-
Today on International Women’s Day, we celebrate the pioneering and trailblazing women at the forefront of drug discovery at HotSpot, as well as across the healthcare industry, whose innovation is essential to the advancement of science and medicine. #IWD2024 #InspireInclusion
-
Hear from Eva Jack, and other inspiring female leaders in #science, this #InternationalDayOfWomenAndGirlsInScience!
At SR One, we're proud to spotlight the incredible women driving innovation in #STEM fields across our #portfoliocompanies. From pioneering research to cutting-edge product development, these women are breaking barriers and paving the way for a more inclusive and diverse #biotech landscape. Their contributions not only inspire us but also showcase the power of diversity in driving #innovation and creating positive change. #WomenInSTEM #womeninbusiness #womeninfinance Maryam Abdul-Kareem, Lyn Baranowski, Athena Countouriotis MD, Natalie Dales, Eva Jack, Zhen Li Arcellx, Avalyn Pharma Inc., Avenzo Therapeutics, ADARx Pharmaceuticals Inc., HotSpot Therapeutics, Inc., Odyssey Therapeutics
-
Taking cues from facial recognition, check out our latest blog post, where we delve into the ways in which pattern recognition technology has enhanced our Smart Allostery platform and facilitated drug discovery at HotSpot: https://lnkd.in/gMBBemcY
Drug Discovery: Taking Inspiration from Facial Recognition - HotSpot Therapeutics
https://www.hotspotthera.com
-
HotSpot Therapeutics, Inc. reposted this
In our latest blog post, Jonathan Montagu, our CEO, reflected on the tremendous potential of targeting protein complexes within signaling pathways, an approach being put into action with our MALT1 inhibitor program. Check it out here: https://lnkd.in/e4css5Mt!
-
In our latest blog post, Jonathan Montagu, our CEO, reflected on the tremendous potential of targeting protein complexes within signaling pathways, an approach being put into action with our MALT1 inhibitor program. Check it out here: https://lnkd.in/e4css5Mt!
-
This weekend, HotSpot scientists presented preclinical data for our highly differentiated MALT1 scaffolding inhibitor. Thank you to all who attended the presentation! To learn more, check out our release here: https://lnkd.in/e8DJ8_CK
-